Half-dose photodynamic therapy versus 577 nm subthreshold pulse laser therapy in treatment-naive patients with central serous chorioretinopathy

Author: Lebriz Altay (Germany)

Co-authors: Vasilena Sitnilska, Petra Schiller, Tim Krohne, Lebriz Altay

Purpose

To compare real-life anatomical and functional outcomes of half-dose photodynamic therapy (HD-PDT) and 577 nm subthreshold pulse laser therapy (SPL) in treatment-naïve patients with central serous chorioretinopathy (CSC).

Setting/Venue

Retrospective

Methods

We retrospectively reviewed consecutive treatment-naïve CSC patients with non-resolving subretinal fluid (SRF)>2 months, who received HD-PDT or SPL treatment. One repetition of the same treatment was allowed in patients with insufficient response. Functional and anatomical outcomes were assessed after first treatment and at final visit

Results

We included 95 patients (HD-PDT, n=49; SPL, n=46). In the HD-PDT and the SPL group, 21 patients (42.9%) and 19 patients (41.3%, P=0.878) exhibited complete resolution of SRF after the first treatment, respectively, 22 patients (44.9%) and 20 patients (43.5%) received a second treatment due to persistent SRF, and the remainder opted for no second treatment despite persistent SRF. Following the second treatment, SRF resolution was observed in 61.2% (n=30) and 60.9% (n=28; P=0.972) of all patients, respectively. Mean BCVA improved significantly in both groups with a similar median change of BCVA of 0.10 logMAR.

Conlusions

High-density 577 nm SPL resulted in as good anatomical and functional treatment and may represent an alternative treatment for CSC.

Financial Disclosure

No Relation